A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.

导出 LinkOut

翻译打印收藏纠错

作者： Aurora,Norman ^[1] ; Mahesh,Seetharam ^[2] ; Jacob,Allred ^[1] ; Jianping,Kong ^[1] ; Mateusz,Opyrchal ^[3] ; Wen Wee,Ma ^[4] ; Yanyan,Lou ^[5] ; Grace K,Dy ^[6] ; Amit,Mahipal ^[7] ; S John,Weroha ^[1] ; Andrea E,Wahner Hendrickson ^[1] ; Joel M,Reid ^[1] ; Alex A,Adjei ^[8]

作者单位： Mayo Clinic, Rochester, MN, USA. ^[1] Mayo Clinic, Phoenix, AZ, USA. ^[2] Indiana University, Indianapolis, USA. ^[3] Cleveland Clinic, Cleveland, OH, USA. ^[4] Mayo Clinic, Jacksonville, FL, USA. ^[5] Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. ^[6] University Hospitals at Case Western University, Cleveland, OH, USA. ^[7] Cleveland Clinic, Cleveland, OH, USA. adjeia2@CCF.org. ^[8]

DOI 10.1038/s44276-024-00107-0

PMID 39809926

发布时间 2025-01-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

BJC reports

2025年3卷1期

1页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.

BJC reports

相似文献

BJC reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.

BJC reports

相似文献

BJC reports

相关期刊

检索历史清除